RT Journal Article
SR Electronic
T1 A multiplex serological assay for the characterization of IgG immune response to SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.23.21262329
DO 10.1101/2021.09.23.21262329
A1 Brochot, Etienne
A1 Souplet, Vianney
A1 Follet, Pauline
A1 Ponthieu, Pauline
A1 Olivier, Christophe
A1 Even, Gaël
A1 Audebert, Christophe
A1 Malbec, Rémi
YR 2021
UL http://medrxiv.org/content/early/2021/09/24/2021.09.23.21262329.abstract
AB Background In the fight against SARS-COV-2, the development of serological assays based on different antigenic domains represent a versatile tool to get a comprehensive picture of the immune response or differentiate infection from vaccination beyond simple diagnosis.Objectives Here we use a combination of the Nucleoprotein (NP), the Spike 1 (S1) and Spike 2 (S2) subunits, and the receptor binding domain (RBD) and N-terminal domain (NTD) of the Spike antigens from the Syrius-CoViDiag® multiplex IgG assay, to follow the immune response to SARS-CoV-2 infection over a long time period and depending on disease severity.Results Using a panel of 209 sera collected from 61 patients up to eight months after infection, we observed that most patients develop an immune response against multiple viral epitope, but anti-S2 antibodies seemed to last longer. For all the tested IgGs, we have found higher titers for hospitalized patients than for non-hospitalized ones. Moreover the combination of the five different IgG titers increased the correlation to the neutralizing antibody titers than if considered individually.Conclusion Multiplex immunoassays have the potential to improve diagnostic performances, especially for ancient infection or mild form of the disease presenting weaker antibody titers. Also the combined detection of anti-NP and anti-Spike-derived domains can be useful to differentiate vaccination from viral infection and accurately assess the antibody potential to neutralize the virus.Competing Interest StatementAuthors Remi Malbec, Gael Even and Christophe Audebert are employees of GD Biotech, while Pauline Ponthieu, Pauline Follet, Vianney Souplet and Christophe Olivier are employees of Innobiochips, providing the CoViDiag assay kits for this study.Funding StatementLaboratory's own ressourceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board of the Amiens University Medical Center (number PI2020_843_0046, 21 April 2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data and results are available in supplementary data.